AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18245417 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained providers
Number of subjects: 418
Study 18245417 — intervention group
Group type: COMPARATOR
Intervention: Control providers
Number of subjects: 418
Study 16408409 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving simulator
Number of subjects: 12
Study 16408409 — intervention group
Group type: COMPARATOR
Intervention: Real driving
Number of subjects: 12
Study 16408409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restricted condition (2 hours)
Number of subjects: 12
Study 16408409 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled habitual sleep (8 hours)
Number of subjects: 12
Study 12635059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency, low-volume ventilation with 100% oxygen
Number of subjects: 75
Study 12635059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency, low-volume ventilation with 21% oxygen
Number of subjects: 75
Study 12635059 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) with 100% oxygen
Number of subjects: 75
Study 12635059 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) with 21% oxygen
Number of subjects: 75
Study 12635059 — intervention group
Group type: COMPARATOR
Intervention: Disconnected from the ventilator during the bypass period
Number of subjects: 75
Study 10784292 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training led by external clinical psychologists
Number of subjects: 0
Study 10784292 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training led by paraprofessionals
Number of subjects: 0
Study 10784292 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 0
Study 8683682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG) instillation (120 mg, weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2)
Number of subjects: 261
Study 8683682 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C instillation (40 mg, weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2)
Number of subjects: 261
Study 8683682 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 261
Study 8683682 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 261
Study 8683682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 261
Study 1993497 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa therapy
Number of subjects: 124
Study 1993497 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 31979294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model with glycemic index (GI) and glycemic load (GL) included
Number of subjects: 124
Study 31979294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model without glycemic index (GI) and glycemic load (GL)
Number of subjects: 124
Study 31979294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model with GI/GL for new patients
Number of subjects: 124
Study 31979294 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model without GI/GL for new patients
Number of subjects: 124
Study 30728377 — intervention group
Group type: EXPERIMENTAL
Intervention: Total anti-HAV detected using Chemiluminescent Enzyme Immunoassay
Number of subjects: 1200
Study 30728377 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals aged 20-59 years
Number of subjects: 1200
Study 30728377 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals aged 70s
Number of subjects: 1200
Study 30728377 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine
Number of subjects: 1200
Study 27040557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) targeting social skills and anxiety
Number of subjects: 25
Study 25627290 — intervention group
Group type: EXPERIMENTAL
Intervention: LSCS group
Number of subjects: 20
Study 25627290 — intervention group
Group type: COMPARATOR
Intervention: LDH group
Number of subjects: 20
Study 23624296 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 27
Study 23624296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21315879 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session computer-based exposure (CBE) treatment; 27-minute session with nine fear-eliciting spider pictures
Number of subjects: 0
Study 21315879 — intervention group
Group type: COMPARATOR
Intervention: Control group exposed to nine neutral pictures
Number of subjects: 0
Study 19608566 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin during IVF and first trimester of pregnancy
Number of subjects: 54
Study 19608566 — intervention group
Group type: COMPARATOR
Intervention: Placebo during IVF and first trimester of pregnancy
Number of subjects: 54
Study 16930908 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐automated liquid handling systems with liquid/liquid extraction (LLE) and gradient liquid chromatography tandem mass spectrometry (LC‐MS/MS) for DEX, DET, and GG.
Number of subjects: 6
Study 16930908 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐automated LLE with LC‐MS/MS
Number of subjects: 6
Study 16930908 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation optimization
Number of subjects: 6
Study 14986194 — intervention group
Group type: EXPERIMENTAL
Intervention: MetaMax II at 100 W
Number of subjects: 29
Study 14986194 — intervention group
Group type: EXPERIMENTAL
Intervention: MetaMax II at 200 W
Number of subjects: 29
Study 14986194 — intervention group
Group type: EXPERIMENTAL
Intervention: MetaMax II at 250 W
Number of subjects: 29
Study 14986194 — intervention group
Group type: EXPERIMENTAL
Intervention: MetaMax II at 325 W
Number of subjects: 29
Study 11549629 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal dihydrotestosterone gel (70 mg daily)
Number of subjects: 37
Study 11549629 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 37
Study 9489974 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2877
Study 9489974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2877
Study 7785133 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant treatment (10% dibunol liniment and 5% ascorbic acid) injected 2 times a day, combined with 500,000 U of ampicillin for purulent sinusitis; injected once a day without antibiotic for catarrhal sinusitis.
Number of subjects: 0
Study 7785133 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (4 ml dioxidine in a single dose for catarrhal sinusitis; 500,000 U ampicillin plus hydrocortisone emulsion 2 times a day for purulent sinusitis).
Number of subjects: 0
Study 3136831 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg recombinant tissue plasminogen activator
Number of subjects: 50
Study 3136831 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg recombinant tissue plasminogen activator
Number of subjects: 50
Study 3136831 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg recombinant tissue plasminogen activator
Number of subjects: 50
Study 3136831 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of recombinant tissue plasminogen activator
Number of subjects: 50
Study 3136831 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion
Number of subjects: 50
Study 3136831 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg and 100 mg doses
Number of subjects: 50
Study 31190781 — intervention group
Group type: EXPERIMENTAL
Intervention: CID- patients (no clinically important deterioration)
Number of subjects: 3769
Study 28872526 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene liners (E1)
Number of subjects: 63
Study 28872526 — intervention group
Group type: COMPARATOR
Intervention: Highly cross-linked liners without vitamin E (ArComXL)
Number of subjects: 63
Study 25587004 — intervention group
Group type: EXPERIMENTAL
Intervention: Jollab
Number of subjects: 133
Study 25587004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 24035110 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical doxycycline hyclate
Number of subjects: 50
Study 24035110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20953874 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral (AL) approach
Number of subjects: 40
Study 20953874 — intervention group
Group type: COMPARATOR
Intervention: Transgluteal (TG) approach
Number of subjects: 40
Study 20953874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AL and TG)
Number of subjects: 40
Study 19617207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hCG (200 IU/l daily)
Number of subjects: 70
Study 19617207 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with rFSH (Puregon) plus a GnRH‐antagonist
Number of subjects: 70
Study 17105694 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet cupping (active group)
Number of subjects: 20
Study 17105694 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study 15257305 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12
Study 15257305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11397890 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 39
Study 11397890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 9438235 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 29
Study 9438235 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fat diet
Number of subjects: 29
Study 9438235 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 29
Study 9438235 — intervention group
Group type: COMPARATOR
Intervention: Overall controlled diets
Number of subjects: 29
Study 8483174 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 99
Study 8483174 — intervention group
Group type: COMPARATOR
Intervention: 1% diphenhydramine
Number of subjects: 99
Study 2446078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0
Study 2446078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30654120 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction (ACLR)
Number of subjects: 121
Study 30654120 — intervention group
Group type: EXPERIMENTAL
Intervention: First 2 years post-ACL injury
Number of subjects: 121
Study 30654120 — intervention group
Group type: EXPERIMENTAL
Intervention: Last 3 years post-ACL injury
Number of subjects: 121
Study 30654120 — intervention group
Group type: COMPARATOR
Intervention: Reference cohort from Osteoarthritis Initiative (OAI)
Number of subjects: 121
Study 28560774 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (Pgp inhibitor)
Number of subjects: 24
Study 28560774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26036434 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Number of subjects: 81
Study 26036434 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 81
Study 26036434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 23941889 — intervention group
Group type: EXPERIMENTAL
Intervention: STN‐DBS ON stimulation
Number of subjects: 18
Study 23941889 — intervention group
Group type: EXPERIMENTAL
Intervention: STN‐DBS OFF stimulation
Number of subjects: 18
Study 23941889 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 18
Study 21308579 — intervention group
Group type: EXPERIMENTAL
Intervention: Food product ads employing nutrition claims with an anchor
Number of subjects: 0
Study 21308579 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchoring successfully evoked
Number of subjects: 0
Study 19850691 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI+IID (Methimazole combined with intrathyroid injection of dexamethasone)
Number of subjects: 191
Study 19850691 — intervention group
Group type: COMPARATOR
Intervention: MMI (Methimazole alone)
Number of subjects: 191
Study 17304779 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isopropyl alcohol (IPA)
Number of subjects: 100
Study 17304779 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron, 4 mg intravenously (Control)
Number of subjects: 100
Study 15066931 — intervention group
Group type: EXPERIMENTAL
Intervention: +ISO (soy protein drink providing 83 mg/day isoflavones)
Number of subjects: 128
Study 15066931 — intervention group
Group type: COMPARATOR
Intervention: -ISO (similar drink with isoflavones removed)
Number of subjects: 128
Study 15066931 — intervention group
Group type: EXPERIMENTAL
Intervention: +ISO
Number of subjects: 128
Study 15066931 — intervention group
Group type: COMPARATOR
Intervention: -ISO
Number of subjects: 128
Study 11755456 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day ethyl eicosapentaenoate (E‐E)
Number of subjects: 115
Study 11755456 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day ethyl eicosapentaenoate (E‐E)
Number of subjects: 115
Study 11755456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 9673662 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI
Number of subjects: 9
Study 9673662 — intervention group
Group type: COMPARATOR
Intervention: PET
Number of subjects: 9
Study 7640117 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hyoscine
Number of subjects: 50
Study 7640117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2376409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (PB)
Number of subjects: 21
Study 367234 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked marijuana
Number of subjects: 8
Study 367234 — intervention group
Group type: COMPARATOR
Intervention: Propranolol pretreatment
Number of subjects: 8
Study 29160303 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 1822
Study 29160303 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 1822
Study 28945881 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT)
Number of subjects: 497
Study 28945881 — intervention group
Group type: COMPARATOR
Intervention: Postremission chemotherapy
Number of subjects: 497
Study 26234442 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (Levemir) and biphasic insulin (NovoMix70)
Number of subjects: 245
Study 26234442 — intervention group
Group type: COMPARATOR
Intervention: Standard care according to the American Diabetes Association recommendations
Number of subjects: 245
Study 23278837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating Pressure Infusion (OPI) method
Number of subjects: 47
Study 21627685 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 hypoglycaemia (blood glucose < 4 mmol/l with no associated symptoms)
Number of subjects: 226
Study 21627685 — intervention group
Group type: COMPARATOR
Intervention: No experience of hypoglycaemia
Number of subjects: 226
Study 21627685 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hypoglycaemia (grade 2 and 3)
Number of subjects: 226
Study 19085723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg)
Number of subjects: 60
Study 19085723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19085723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Fluvoxamine and Placebo)
Number of subjects: 60
Study 16872336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 51
Study 16872336 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (Control)
Number of subjects: 51
Study 12756382 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (0.1 mg/kg/dose) three times per day for 7 days
Number of subjects: 129
Study 12756382 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times per day for 7 days
Number of subjects: 129
Study 12756382 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 129
Study 12756382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 11123495 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg testosterone enanthanate, intramuscularly every 2 weeks)
Number of subjects: 22
Study 11123495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscularly every 2 weeks)
Number of subjects: 22
Study 10968046 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of Augmentin intravenously
Number of subjects: 200
Study 10968046 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 200
Study 8467321 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (ACE-inhibition)
Number of subjects: 16
Study 8467321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2946486 — intervention group
Group type: EXPERIMENTAL
Intervention: Wanbei
Number of subjects: 304
Study 2946486 — intervention group
Group type: COMPARATOR
Intervention: Chuanbei
Number of subjects: 304
Study 31610337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus suppositories (2mg, n=43)
Number of subjects: 85
Study 31610337 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone suppositories (3mg, n=42)
Number of subjects: 85
Study 30308384 — intervention group
Group type: EXPERIMENTAL
Intervention: RAW (Benzodiazepine-resistant alcohol withdrawal)
Number of subjects: 736
Study 26608876 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine (40 mg) without sufentanil
Number of subjects: 60
Study 26608876 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine (40 mg) with sufentanil (1 μg)
Number of subjects: 60
Study 26608876 — intervention group
Group type: COMPARATOR
Intervention: hyperbaric bupivacaine (7.5 mg) with sufentanil (1 μg)
Number of subjects: 60
Study 25038357 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin, 2 mg, subcutaneously daily for 6 months
Number of subjects: 50
Study 25038357 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 23233650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg lapatinib for 28-42 days before surgery
Number of subjects: 31
Study 21388821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile pulmonary perfusion (PPP) with oxygenated blood
Number of subjects: 30
Study 21388821 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB
Number of subjects: 30
Study 18636367 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in unprocessed fruits and vegetables
Number of subjects: 11
Study 18636367 — intervention group
Group type: COMPARATOR
Intervention: High bioaccessible diet (animal foods and fruit juices)
Number of subjects: 11
Study 16597662 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow tinted intraocular lenses (HOYA YA60BB)
Number of subjects: 74
Study 16597662 — intervention group
Group type: COMPARATOR
Intervention: Non-tinted intraocular lenses (VA60BB)
Number of subjects: 74
Study 12651787 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-initiated pre-conception counselling
Number of subjects: 1206
Study 10882838 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic amphetamine abusers
Number of subjects: 0
Study 10882838 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic heroin abusers
Number of subjects: 0
Study 10882838 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 8635446 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight level at 8.2 kg
Number of subjects: 12
Study 8635446 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight level at 3 kg
Number of subjects: 12
Study 8635446 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight level at 1.5 kg
Number of subjects: 12
Study 8635446 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight level at 0.25 kg
Number of subjects: 12
Study 8635446 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight levels (0.01, 0.5, 1, and 15 kg) considered for further analysis
Number of subjects: 12
Study 1546413 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally applied scopolamine (Scopoderm)
Number of subjects: 50
Study 1546413 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study 2887941 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril 25 mg twice daily
Number of subjects: 20
Study 2887941 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg once daily
Number of subjects: 20
Study 2887941 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 200 mg twice daily
Number of subjects: 20
Study 2887941 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol 10 mg twice daily
Number of subjects: 20
Study 2887941 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31755321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0
Study 31755321 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 29200066 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain
Number of subjects: 86
Study 29200066 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain rate (SR)
Number of subjects: 86
Study 29200066 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 86
Study 27955636 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventative intervention program targeting personality traits associated with adolescent alcohol use
Number of subjects: 150
Study 27955636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 27955636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks and neuroimaging scans conducted at baseline, 24-month, and 48-month follow-up
Number of subjects: 150
Study 24691844 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-462206 200 mg and above
Number of subjects: 44
Study 24691844 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-462206 400-1000 mg
Number of subjects: 44